II
ALXN

Inspire Investing’s Alexion Pharmaceuticals ALXN Stock Holding History

Inspire Investing’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,395
Closed -$3.56M – 974
2021
Q2 		$3.56M Buy
19,395
+1,300
+7% +$223K 0.47% 39
2021
Q1 		$2.77M Buy
18,095
+4,092
+29% +$633K 0.42% 46
2020
Q4 		$2.19M Buy
14,003
+1,301
+10% +$167K 0.48% 32
2020
Q3 		$1.45M Buy
12,702
+1,177
+10% +$127K 0.4% 49
2020
Q2 		$1.29M Buy
11,525
+3,147
+38% +$334K 0.45% 43
2020
Q1 		$752K Sell
8,378
-1,720
-17% -$169K 0.3% 55
2019
Q4 		$1.09M Buy
10,098
+979
+11% +$105K 0.39% 59
2019
Q3 		$893K Buy
9,119
+1,478
+19% +$167K 0.34% 68
2019
Q2 		$1M Buy
7,641
+719
+10% +$92.7K 0.42% 45
2019
Q1 		$936K Buy
6,922
+1,118
+19% +$139K 0.43% 41
2018
Q4 		$565K Buy
5,804
+633
+12% +$74.8K 0.38% 54
2018
Q3 		$719K Buy
5,171
+820
+19% +$103K 0.44% 37
2018
Q2 		$540K Buy
4,351
+2,168
+99% +$253K 0.38% 47
2018
Q1 		$243K Buy
2,183
+491
+29% +$58.7K 0.25% 136
2017
Q4 		$202K Buy
+1,692
New +$206K 0.17% 74

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Inspire Investing's ALXN Position: Q3 2021 in Review

Inspire Investing sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 19,395 shares — an estimated $3.56M sold.

Inspire Investing first reported a position in ALXN in Q4 2017 and held it in 15 quarters. The position peaked at $3.56M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Inspire Investing reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Inspire Investing sold 19,395 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.56M.
  • Inspire Investing first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 15 quarters.
  • Inspire Investing's Alexion Pharmaceuticals position peaked at $3.56M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Inspire Investing's 13F filing for Q3 2021, filed 9 Nov 2021.